30 results about "Preventing initiation" patented technology

A mobile station for transferring delay-sensitive data to a wireless communications network is provided with an uplink resource release controller that selectively inhibits release of an uplink resource in order to meet requirements of a delay-sensitive data application, such as a VoIP or streaming application. In one embodiment, the uplink resource release controller causes dummy blocks to be written to a data buffer to prevent initiation of a countdown process. By intelligently controlling resource release, delay-sensitive data may be transmitted in a more reliable fashion, thereby increasing application performance.

The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.

An implantable neurostimulator-implemented method for managing tachyarrhythmias through vagus nerve stimulation is provided. An implantable neurostimulator, including a pulse generator, is configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers of a patient's cervical vagus nerve. Operating modes of the pulse generator are stored. A maintenance dose of the electrical therapeutic stimulation is delivered to the vagus nerve via the pulse generator to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses. A restorative dose of the electrical therapeutic stimulation is delivered to prevent initiation of or disrupt tachyarrhythmia through periodic electrical pulses delivered at higher intensity than the maintenance dose. The patient's normative physiology is monitored via a physiological sensor, and upon sensing a condition indicative of tachyarrhythmia, is switched to delivering the restorative dose to the vagus nerve.

An initiator including a housing adapted to be received in an igniter or rocket motor, at least one charge at a distal end of the housing, an electro-explosive device behind the charge for detonating the charge when subject to a voltage HV, and a pressure bulkhead behind the electro-explosive device. An electronic subsystem in the housing is connected to the electro-explosive device through the bulkhead and includes a lead for providing the voltage HV to the electro-explosive device to initiate it, and a switch in the lead which does not conduct if errant voltages are present on the lead to prevent initiation of the electro-explosive device until the correct voltage HV is present.

The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an amyloid beta peptide, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.

The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.